European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease.
The therapy is the first approved pharmacological treatment for cALD in the European Union (EU) with approval based on results from the Phase 2/3 NEXUS1 study and additional real-world evidence from compassionate use programmes.
The first European launch is expected in Germany by the end of the year, with additional launches in Europe anticipated pending completion of national reimbursement negotiations
Leriglitazone is due to be assessed by NICE early next year and Alex TLC are involved in the process as the patient voice.
